106 related articles for article (PubMed ID: 25297324)
1. Clinical validation of the Cervista HPV HR test according to the international guidelines for human papillomavirus test requirements for cervical cancer screening.
Boers A; Wang R; Slagter-Menkema L; van Hemel BM; Ghyssaert H; van der Zee AG; Wisman GB; Schuuring E
J Clin Microbiol; 2014 Dec; 52(12):4391-3. PubMed ID: 25297324
[TBL] [Abstract][Full Text] [Related]
2. Cervista HPV HR test for cervical cancer screening: a comparative study in the Catalonian population.
Alameda F; Garrote L; Mojal S; Sousa C; Muset M; LLoveras B; Bellosillo B; Saldanha C; Carreras R; Serrano S
Arch Pathol Lab Med; 2015 Feb; 139(2):241-4. PubMed ID: 25611107
[TBL] [Abstract][Full Text] [Related]
3. Which high-risk HPV assays fulfil criteria for use in primary cervical cancer screening?
Arbyn M; Snijders PJ; Meijer CJ; Berkhof J; Cuschieri K; Kocjan BJ; Poljak M
Clin Microbiol Infect; 2015 Sep; 21(9):817-26. PubMed ID: 25936581
[TBL] [Abstract][Full Text] [Related]
4. Comparing the Cervista HPV HR test and Hybrid Capture 2 assay in a Dutch screening population: improved specificity of the Cervista HPV HR test by changing the cut-off.
Boers A; Slagter-Menkema L; van Hemel BM; Belinson JL; Ruitenbeek T; Buikema HJ; Klip H; Ghyssaert H; van der Zee AG; de Bock GH; Wisman GB; Schuuring E
PLoS One; 2014; 9(7):e101930. PubMed ID: 25051098
[TBL] [Abstract][Full Text] [Related]
5. Clinical validation of the HPV-risk assay, a novel real-time PCR assay for detection of high-risk human papillomavirus DNA by targeting the E7 region.
Hesselink AT; Berkhof J; van der Salm ML; van Splunter AP; Geelen TH; van Kemenade FJ; Bleeker MG; Heideman DA
J Clin Microbiol; 2014 Mar; 52(3):890-6. PubMed ID: 24391196
[TBL] [Abstract][Full Text] [Related]
6. Validation of intra- and inter-laboratory reproducibility of the Xpert HPV assay according to the international guidelines for cervical cancer screening.
Akbari A; Vanden Broeck D; Benoy I; Padalko E; Bogers J; Arbyn M
Virol J; 2018 Oct; 15(1):166. PubMed ID: 30373616
[TBL] [Abstract][Full Text] [Related]
7. Clinical validation of the cobas 4800 HPV test for cervical screening purposes.
Heideman DA; Hesselink AT; Berkhof J; van Kemenade F; Melchers WJ; Daalmeijer NF; Verkuijten M; Meijer CJ; Snijders PJ
J Clin Microbiol; 2011 Nov; 49(11):3983-5. PubMed ID: 21880968
[TBL] [Abstract][Full Text] [Related]
8. Comparison of clinical performance of Abbott RealTime High Risk HPV test with that of hybrid capture 2 assay in a screening setting.
Carozzi FM; Burroni E; Bisanzi S; Puliti D; Confortini M; Giorgi Rossi P; Sani C; Scalisi A; Chini F
J Clin Microbiol; 2011 Apr; 49(4):1446-51. PubMed ID: 21325553
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the analytical and clinical performance of five tests for the detection of human papillomavirus genital infection.
Del Pino M; Alonso I; Rodriguez-Trujillo A; Bernal S; Geraets D; Guimerà N; Torne A; Ordi J
J Virol Methods; 2017 Oct; 248():238-243. PubMed ID: 28739302
[TBL] [Abstract][Full Text] [Related]
10. Clinical experience with the Cervista HPV HR assay: correlation of cytology and HPV status from 56,501 specimens.
Youens KE; Hosler GA; Washington PJ; Jenevein EP; Murphy KM
J Mol Diagn; 2011 Mar; 13(2):160-6. PubMed ID: 21354050
[TBL] [Abstract][Full Text] [Related]
11. Aptima HPV Assay versus Hybrid Capture
Cook DA; Smith LW; Law J; Mei W; van Niekerk DJ; Ceballos K; Gondara L; Franco EL; Coldman AJ; Ogilvie GS; Jang D; Chernesky M; Krajden M
J Clin Virol; 2017 Feb; 87():23-29. PubMed ID: 27988420
[TBL] [Abstract][Full Text] [Related]
12. Intra- and interlaboratory reproducibility evaluation toward international validation status of the AmpFire assay.
Chung PYJ; Dhillon SK; Baraquin A; Tkachenka Y; Jacquot K; Prétet JL; Broeck DV; Arbyn M
J Med Virol; 2024 Jun; 96(6):e29688. PubMed ID: 38847316
[TBL] [Abstract][Full Text] [Related]
13. Comparison of clinical and analytical performance of the Abbott Realtime High Risk HPV test to the performance of hybrid capture 2 in population-based cervical cancer screening.
Poljak M; Ostrbenk A; Seme K; Ucakar V; Hillemanns P; Bokal EV; Jancar N; Klavs I
J Clin Microbiol; 2011 May; 49(5):1721-9. PubMed ID: 21430098
[TBL] [Abstract][Full Text] [Related]
14. Clinical validation of a type-specific real-time quantitative human papillomavirus PCR against the performance of hybrid capture 2 for the purpose of cervical cancer screening.
Depuydt CE; Benoy IH; Beert JF; Criel AM; Bogers JJ; Arbyn M
J Clin Microbiol; 2012 Dec; 50(12):4073-7. PubMed ID: 23052314
[TBL] [Abstract][Full Text] [Related]
15. Clinical validation of REALQUALITY RQ-HPV Screen according to the international guidelines for human papillomavirus DNA test requirements for cervical screening.
Iacobellis M; Violante C; Notarachille G; Simone A; Scarfì R; Giuffrè G
Virol J; 2018 Mar; 15(1):48. PubMed ID: 29558950
[TBL] [Abstract][Full Text] [Related]
16. Prior cervical cytology and high-risk HPV testing results for 311 patients with invasive cervical adenocarcinoma: a multicenter retrospective study from China's largest independent operator of pathology laboratories.
Xie F; Zhang L; Zhao D; Wu X; Wei M; Zhang X; Wu X; Fang H; Xu X; Yang M; Qi D
BMC Infect Dis; 2019 Nov; 19(1):962. PubMed ID: 31711435
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of a multiplex real time PCR assay for the detection of human papillomavirus infections on self-collected cervicovaginal lavage samples.
Jentschke M; Soergel P; Hillemanns P
J Virol Methods; 2013 Oct; 193(1):131-4. PubMed ID: 23707925
[TBL] [Abstract][Full Text] [Related]
18. [Investigation of human papillomavirus prevalence in women in Eskişehir, Turkey by Pap smear, hybrid capture 2 test and consensus real-time polymerase chain reaction and typing with pyrosequencing method].
Aslan FG; Us T; Kaşifoğlu N; Özalp SS; Akgün Y; Öge T
Mikrobiyol Bul; 2016 Jan; 50(1):73-85. PubMed ID: 27058331
[TBL] [Abstract][Full Text] [Related]
19. Assessment of a new low-cost, PCR-based strategy for high-risk human papillomavirus DNA detection for cervical cancer prevention.
Surriabre P; Torrico A; Vargas T; Ugarte F; Rodriguez P; Fontaine V
BMC Infect Dis; 2019 Oct; 19(1):842. PubMed ID: 31615443
[TBL] [Abstract][Full Text] [Related]
20. Assessment of the Roche Linear Array HPV Genotyping Test within the VALGENT framework.
Xu L; Oštrbenk A; Poljak M; Arbyn M
J Clin Virol; 2018 Jan; 98():37-42. PubMed ID: 29241150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
